These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 29728798)
21. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. Cecchin E; Innocenti F; D'Andrea M; Corona G; De Mattia E; Biason P; Buonadonna A; Toffoli G J Clin Oncol; 2009 May; 27(15):2457-65. PubMed ID: 19364970 [TBL] [Abstract][Full Text] [Related]
22. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. Toffoli G; Cecchin E; Gasparini G; D'Andrea M; Azzarello G; Basso U; Mini E; Pessa S; De Mattia E; Lo Re G; Buonadonna A; Nobili S; De Paoli P; Innocenti F J Clin Oncol; 2010 Feb; 28(5):866-71. PubMed ID: 20038727 [TBL] [Abstract][Full Text] [Related]
23. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402 [TBL] [Abstract][Full Text] [Related]
24. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Toffoli G; Sharma MR; Marangon E; Posocco B; Gray E; Mai Q; Buonadonna A; Polite BN; Miolo G; Tabaro G; Innocenti F Clin Cancer Res; 2017 Feb; 23(4):918-924. PubMed ID: 27507617 [No Abstract] [Full Text] [Related]
25. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. Okuyama Y; Hazama S; Nozawa H; Kobayashi M; Takahashi K; Fujikawa K; Kato T; Nagata N; Kimura H; Oba K; Sakamoto J; Mishima H Jpn J Clin Oncol; 2011 Apr; 41(4):477-82. PubMed ID: 21303789 [TBL] [Abstract][Full Text] [Related]
26. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. Boige V; Mendiboure J; Pignon JP; Loriot MA; Castaing M; Barrois M; Malka D; Trégouët DA; Bouché O; Le Corre D; Miran I; Mulot C; Ducreux M; Beaune P; Laurent-Puig P J Clin Oncol; 2010 May; 28(15):2556-64. PubMed ID: 20385995 [TBL] [Abstract][Full Text] [Related]
27. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831 [TBL] [Abstract][Full Text] [Related]
28. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Kweekel DM; Koopman M; Antonini NF; Van der Straaten T; Nortier JW; Gelderblom H; Punt CJ; Guchelaar HJ Br J Cancer; 2008 Oct; 99(8):1316-21. PubMed ID: 18797455 [TBL] [Abstract][Full Text] [Related]
29. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239 [TBL] [Abstract][Full Text] [Related]
30. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258 [TBL] [Abstract][Full Text] [Related]
31. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Glimelius B; Garmo H; Berglund A; Fredriksson LA; Berglund M; Kohnke H; Byström P; Sørbye H; Wadelius M Pharmacogenomics J; 2011 Feb; 11(1):61-71. PubMed ID: 20177420 [TBL] [Abstract][Full Text] [Related]
32. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Sunakawa Y; Ichikawa W; Fujita K; Nagashima F; Ishida H; Yamashita K; Mizuno K; Miwa K; Kawara K; Akiyama Y; Araki K; Yamamoto W; Miya T; Narabayashi M; Ando Y; Hirose T; Saji S; Sasaki Y Cancer Chemother Pharmacol; 2011 Aug; 68(2):279-84. PubMed ID: 20957480 [TBL] [Abstract][Full Text] [Related]
33. [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. Wang Y; Xu JM; Shen L; Xu N; Wang JW; Jiao SC; Zhang JS; Song ST; Li J; Bao HY; Yang L; Li F Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):913-6. PubMed ID: 18478930 [TBL] [Abstract][Full Text] [Related]
34. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091 [TBL] [Abstract][Full Text] [Related]
35. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. Tokunaga R; Cao S; Naseem M; Lo JH; Battaglin F; Puccini A; Berger MD; Soni S; Millstein J; Zhang W; Stintzing S; Loupakis F; Cremolini C; Heinemann V; Falcone A; Lenz HJ Clin Colorectal Cancer; 2019 Mar; 18(1):e8-e19. PubMed ID: 30293873 [TBL] [Abstract][Full Text] [Related]
36. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294 [TBL] [Abstract][Full Text] [Related]
37. Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype. Roncato R; Cecchin E; Montico M; De Mattia E; Giodini L; Buonadonna A; Solfrini V; Innocenti F; Toffoli G Clin Pharmacol Ther; 2017 Jul; 102(1):123-130. PubMed ID: 28074472 [TBL] [Abstract][Full Text] [Related]
38. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541 [TBL] [Abstract][Full Text] [Related]
39. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer. Ma CJ; Huang CW; Yeh YS; Tsai HL; Hu HM; Wu IC; Cheng TL; Wang JY Oncol Res; 2017 May; 25(5):673-679. PubMed ID: 27938508 [TBL] [Abstract][Full Text] [Related]
40. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Fujita K; Nagashima F; Yamamoto W; Endo H; Sunakawa Y; Yamashita K; Ishida H; Mizuno K; Matsunaga M; Araki K; Tanaka R; Ichikawa W; Miya T; Narabayashi M; Akiyama Y; Kawara K; Ando Y; Sasaki Y Biol Pharm Bull; 2008 Nov; 31(11):2137-42. PubMed ID: 18981587 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]